Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial-Reference-Cited by-同舟云学术

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial

Published:2017-04 Issue:4 Volume:5 Page:251-260
ISSN:2213-8587
Container-title:The Lancet Diabetes & Endocrinology
language:en
Short-container-title:The Lancet Diabetes & Endocrinology

Author:

Sorli Christopher,Harashima Shin-ichi,Tsoukas George M,Unger Jeffrey,Karsbøl Julie Derving,Hansen Thomas,Bain Stephen C

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference32 articles.

1. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes;Inzucchi;Diabetes Care,2015

2. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus;Endocr Pract,2007

3. GLP-1 receptor activated insulin secretion from pancreatic beta-cells: mechanism and glucose dependence;Meloni;Diabetes Obes Metab,2013

4. The effect of glucagon-like peptide 1 receptor agonists on weight loss in type 2 diabetes: a systematic review and mixed treatment comparison meta-analysis;Potts;PLoS One,2015

5. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults;van Can;Int J Obes (Lond),2014

Cited by 423 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Diabetic Retinopathy at a Tertiary Care Center;Ophthalmology Science;2024-11

2. Celastrol: A century-long journey from the isolation to the biotechnological production and the development of an antiobesity drug;Current Opinion in Plant Biology;2024-10

3. Effect of Semaglutide on Physical Function, Body Composition, and Biomarkers of Aging in Older Adults With Overweight and Insulin Resistance: Protocol for an Open-Labeled Randomized Controlled Trial;JMIR Research Protocols;2024-09-13

4. Comparative risk of infection of medications used for type 2 diabetes;Expert Opinion on Drug Safety;2024-09-11

5. Semaglutide use in people with obesity and type 2 diabetes from real‐world utilization data: An analysis of the All of US Program;Diabetes, Obesity and Metabolism;2024-09-09